MAGEA10 expression is a predictive marker of early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer

[1]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2018 (5th edition) , 2020, Gastric Cancer.

[2]  T. Sugino,et al.  Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients , 2019, Cancer science.

[3]  L. Lundell,et al.  Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow‐up after surgery for upper gastrointestinal cancer (EUFURO study) , 2019, The British journal of surgery.

[4]  M. Kanda,et al.  Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer , 2019, AntiCancer Research.

[5]  M. Kanda,et al.  PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer , 2019, Annals of Surgical Oncology.

[6]  K. Muro,et al.  Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study , 2018, International Journal of Clinical Oncology.

[7]  Masakazu Yamamoto,et al.  Near-Comprehensive Resequencing of Cancer-Associated Genes in Surgically Resected Metastatic Liver Tumors of Gastric Cancer. , 2019, American Journal of Pathology.

[8]  Y. Kodera,et al.  Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Kazuhiro Yoshida,et al.  Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. , 2019, The lancet. Gastroenterology & hepatology.

[10]  M. Sang,et al.  Tumor suppressive miR-6775-3p inhibits ESCC progression through forming a positive feedback loop with p53 via MAGE-A family proteins , 2018, Cell Death & Disease.

[11]  M. Sang,et al.  Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs , 2018, Clinical Epigenetics.

[12]  A. Hauschild,et al.  MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[13]  M. Kanda,et al.  SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells , 2018, Oncogene.

[14]  Masahiko Watanabe,et al.  Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen , 2017, World journal of gastroenterology.

[15]  Shujiro Okuda,et al.  Actionable gene-based classification toward precision medicine in gastric cancer , 2017, Genome Medicine.

[16]  K. Yamaguchi,et al.  Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors , 2017, Scientific Reports.

[17]  H. Imamura,et al.  TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study , 2017, Oncotarget.

[18]  H. Imamura,et al.  TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study , 2017, Oncotarget.

[19]  G. Hanna,et al.  Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England , 2017, Gastric Cancer.

[20]  R. Makuuchi,et al.  Early detection of nonperitoneal recurrence may contribute to survival benefit after curative gastrectomy for gastric cancer , 2017, Gastric Cancer.

[21]  M. Kanda,et al.  GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer , 2017, Scientific Reports.

[22]  J. Wang,et al.  Identification of MAGEA12 as a prognostic outlier gene in gastric cancers. , 2016, Neoplasma.

[23]  K. Yamaguchi,et al.  Integrated next-generation sequencing analysis of whole exome and 409 cancer-related genes. , 2016, Biomedical research.

[24]  K. Yamaguchi,et al.  Optimizing an ion semiconductor sequencing data analysis method to identify somatic mutations in the genomes of cancer cells in clinical tissue samples. , 2016, Biomedical research.

[25]  G. Hanna,et al.  Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis , 2016, Annals of surgery.

[26]  Moon Soo Kim,et al.  Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[27]  S. Chiou,et al.  Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers , 2015, Oncotarget.

[28]  H. Sakamoto,et al.  Multicentre analysis of long‐term outcome after surgical resection for gastric cancer liver metastases , 2015, The British journal of surgery.

[29]  T. Nakajima,et al.  Implementation of individualized medicine for cancer patients by multiomics-based analyses—the Project HOPE—. , 2014, Biomedical research.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[31]  Dazhi Xu,et al.  Time-varying pattern of recurrence risk for gastric cancer patients , 2013, Medical Oncology.

[32]  L. Terracciano,et al.  MAGE‐A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies , 2011, International journal of cancer.

[33]  D. Speiser,et al.  Pattern and clinical significance of cancer‐testis gene expression in head and neck squamous cell carcinoma , 2011, International journal of cancer.

[34]  H. Kuwano,et al.  Clinical Significance of Melanoma Antigen-Encoding Gene-1 (MAGE-1) Expression and its Correlation with Poor Prognosis in Differentiated Advanced Gastric Cancer , 2011, Annals of Surgical Oncology.

[35]  T. Hupp,et al.  Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. , 2010, Cancer research.

[36]  S. Iida,et al.  MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer , 2008, British Journal of Cancer.

[37]  H. Lee,et al.  Expression of family A melanoma antigen in human gastric carcinoma. , 2005, Anticancer research.

[38]  J. Wiltfang,et al.  Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. , 2005, International journal of oncology.

[39]  B. Simon,et al.  Expression Spectrum and Methylation-Dependent Regulation of Melanoma Antigen-Encoding Gene Family Members in Pancreatic Cancer Cells , 2002, Pancreatology.

[40]  K. Sugimachi,et al.  Expression spectrum of melanoma antigen-encoding gene family members in colorectal carcinoma. , 1998, Archives of pathology & laboratory medicine.

[41]  K. Mimori,et al.  Expression of MAGE genes in human colorectal carcinoma. , 1996, Annals of surgery.

[42]  H. Kitaoka,et al.  Clinicopathologic studies of gastric cancer with metastasis to the liver--based on the cases detected at initial surgery. , 1984, Japanese journal of clinical oncology.